Compare CCCC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | VNDA |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.6M | 301.1M |
| IPO Year | 2020 | 2005 |
| Metric | CCCC | VNDA |
|---|---|---|
| Price | $3.06 | $4.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $12.86 | $11.75 |
| AVG Volume (30 Days) | ★ 2.0M | 819.7K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $35,947,000.00 | ★ $216,105,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | N/A | $35.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.02 | ★ 8.72 |
| 52 Week Low | $1.69 | $4.27 |
| 52 Week High | $5.17 | $9.91 |
| Indicator | CCCC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 33.34 |
| Support Level | $2.88 | $4.45 |
| Resistance Level | $3.20 | $5.37 |
| Average True Range (ATR) | 0.22 | 0.17 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 54.54 | 20.41 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.